Tsz Kan Fung

Tsz Kan Fung

Auto-generated profile, based on publicly available information

Tsz Kan Fung

Leukemia & Stem Cell Biology, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
BZBernd B. Zeisig
Bernd B. Zeisig
TFTsz Kan Fung
Tsz Kan Fung
MZMagdalena Zarowiecki
Magdalena Zarowiecki
CTChiou Tsun Tsai
Chiou Tsun Tsai
HLHuacheng Luo
Huacheng Luo
CSChi Wai Eric So
Chi Wai Eric So
Chemoresistant human CD34 −/lo /CD38 + MLL leukemic stem cells originate from HSCs and can be resensitized by targeting ABCC3 with fidaxomicin.

19 September 2024 in American Journal of Transplantation
Verified
Journal Article
Open access
AKAda Sera Kurt
Ada Sera Kurt
PRPaula Ruiz
Paula Ruiz
ELEmmanuelle Landmann
Emmanuelle Landmann
MEMarwa Elgosbi
Marwa Elgosbi
TFTsz Kan Fung
Tsz Kan Fung
ASAlberto Sanchez-Fueyo
Alberto Sanchez-Fueyo
Conferring alloantigen-specificity to ex vivo expanded CD4+CD25+Foxp3+ Tregs increases their capacity to counteract effector alloimmune responses following adoptive transfer into transplant recipients. Three strategies are currently undergoing clinical development, which involve: 1) expanding Tregs in the presence of donor B cells (donor alloantigen-reactive (DAR-Tregs)); 2) culturing Tregs with donor cells in the presence of co-stimulation blockade (CSB-Tregs); and 3) transducing Tregs with an HLA-A2-specific chimeric antigen receptor (CAR-Tregs). Our goal here was to assess the relative potency of each of these manufactured Treg products both in vitro and in vivo. As compared to polyclonal Tregs, all 3 manufacture strategies increased the precursor frequency of alloreactive Tregs, and this was proportional to the overall in vitro immunosuppressive properties of the cell products. Accordingly, CAR-Tregs, which contained the highest frequency of donor-reactive Tregs, exhibited the strongest suppressive effects on a cell-per-cell basis. Similarly, in an in vivo mouse model of GvHD, infusion of CAR-Tregs conferred a significantly longer recipient survival than any other Treg product. Our results highlighting the alloantigen-reactivity and associated immunosuppressive properties of different manufactured Treg products have implications for the mechanistic interpretation of currently ongoing clinical trials in transplantation.

1 January 2021 in Bio-Protocol
Verified
Journal Article
Open access
BZBernd Zeisig
Bernd Zeisig
TFTsz Fung
Tsz Fung
ETEstelle Troadec
Estelle Troadec
CSChi So
Chi So
An open platform for life scientists to share, find,and discuss research protocols